封面
市场调查报告书
商品编码
1703266

系统性幼年特发性关节炎市场-全球产业规模、份额、趋势、机会和预测,按治疗类型、给药途径、配销通路、地区和竞争细分,2020 年至 2030 年

Systemic Juvenile Idiopathic Arthritis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球系统性幼年特发性关节炎 (sJIA) 市值为 18.3 亿美元,预计到 2030 年将达到 24 亿美元,预测期内年复合成长率(CAGR) 为 4.61%。该市场涵盖系统性幼年特发性关节炎(一种罕见且严重的幼年特发性关节炎亚型)的发展、诊断、治疗和管理。

市场概览
预测期 2026-2030
2024年市场规模 18.3亿美元
2030年市场规模 24亿美元
2025-2030 年复合年增长率 4.61%
成长最快的领域 网路药局
最大的市场 北美洲

sJIA 是一种复杂的自体免疫疾病,主要影响儿童,其特征是全身性发炎、高烧、皮疹和关节疼痛,并可能引发器官损伤等併发症。市场涵盖广泛的治疗解决方案,包括旨在改善患者治疗效果和生活品质的药品、生物製剂、医疗器材和支持性护理策略。

关键市场驱动因素

生物疗法的进展

主要市场挑战

治疗费用高昂

主要市场趋势

个人化医疗

目录

第 1 章:产品概述

第二章:研究方法

第三章:执行摘要

第四章:顾客之声

第五章:全球系统性幼年特发性关节炎市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依治疗类型(药物治疗{抗发炎药物(NSAIDS)、肿瘤坏死因子(TNF)阻断剂、肌肉鬆弛剂、免疫抑制剂、改善病情的抗风湿药物、其他}、生物製剂、其他)
    • 依给药途径(口服、注射、其他)
    • 按配销通路(医院药房、零售药房、网路药房)
    • 按公司分类(2024)
    • 按地区
  • 市场地图

第六章:北美系统性幼年特发性关节炎市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章:欧洲系统性幼年特发性关节炎市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章:亚太系统性幼年特发性关节炎市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章:南美洲系统性幼年特发性关节炎市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章:中东和非洲系统性幼年特发性关节炎市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 13 章: 大环境分析

第 14 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章:竞争格局

  • Novartis AG
  • Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Bristol - Myers Squibb Company
  • Cadila Healthcare Ltd.
  • Genetech, Inc.
  • LATAM Pharma
  • Alteogen Inc.
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.

第 16 章:策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 16786

Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market was valued at USD 1.83 billion in 2024 and is projected to reach USD 2.40 billion by 2030, registering a compound annual growth rate (CAGR) of 4.61% during the forecast period. This market encompasses the development, diagnosis, treatment, and management of systemic JIA-a rare and severe subtype of juvenile idiopathic arthritis.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.83 Billion
Market Size 2030USD 2.40 Billion
CAGR 2025-20304.61%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

sJIA is a complex autoimmune condition primarily affecting children and is marked by systemic inflammation, high fevers, skin rashes, and joint pain, with potential complications including organ damage. The market spans a broad spectrum of therapeutic solutions, including pharmaceuticals, biologics, medical devices, and supportive care strategies aimed at improving patient outcomes and quality of life.

Key Market Drivers

Advancements in Biologic Therapies

The increasing global burden of chronic autoimmune diseases is a key contributor to the growth of the sJIA market. Although systemic JIA is a rare pediatric autoimmune condition, it benefits from broader developments in autoimmune disease research and treatment.

According to a study published in Frontiers in Immunology (PMC9918670), the incidence of autoimmune diseases has increased by 19.1%, with a 12.5% rise in prevalence annually. This trend has intensified global focus and investment in autoimmune research, accelerating the development of new treatment approaches for conditions such as sJIA.

Research into more common autoimmune disorders-such as lupus and rheumatoid arthritis-has uncovered shared immunological pathways that are informing the development of novel and repurposed therapies for sJIA. Healthcare systems are also shifting toward integrated, patient-centered chronic disease management models, prioritizing early diagnosis, personalized care plans, and coordinated treatment approaches.

In the United States, the CDC reports that approximately 220,000 children and adolescents live with arthritis-related conditions, including sJIA (MMWR Morb Mortal Wkly Rep 2023;72:793-798). This growing pediatric population is prompting improved screening and referral systems, which in turn are enhancing early detection and treatment outcomes.

Pharmaceutical companies are responding to this demand by investing heavily in biologics and other targeted therapies specifically designed for pediatric autoimmune conditions. These innovations are reshaping the treatment landscape, improving clinical outcomes, and enhancing quality of life for affected children.

Key Market Challenges

High Treatment Costs

One of the most significant barriers to effective care in the Global sJIA Market is the high cost associated with treatment. Managing sJIA typically involves a comprehensive, multidisciplinary approach, including medications to control systemic inflammation and prevent long-term complications.

A major cost driver is the use of biologic therapies, particularly IL-1 and IL-6 inhibitors, which have proven highly effective in treating sJIA. However, these advanced biologics are among the most expensive drugs on the market and often require long-term administration, leading to a substantial financial burden for patients and healthcare systems.

Beyond the cost of medications, managing sJIA often involves routine monitoring, imaging studies, physical therapy, and consultations with multiple specialists. These ancillary costs can further strain healthcare budgets and impose significant financial challenges on families.

Key Market Trends

Personalized Medicine

Personalized medicine is increasingly shaping the future of the sJIA market by offering more tailored and effective treatment approaches based on an individual's genetic, molecular, and clinical profile. This patient-specific strategy is helping optimize therapeutic outcomes while reducing risks associated with traditional trial-and-error treatment methods.

In sJIA care, the use of advanced molecular and genetic profiling tools enables clinicians to better understand disease mechanisms and identify actionable molecular targets. This facilitates the development of highly specialized treatment plans that address the unique disease pathways of each patient.

A key advantage of personalized medicine is its predictive capability-allowing healthcare providers to determine which patients are most likely to respond favorably to specific biologics or immunosuppressive therapies. This not only enhances treatment efficacy but also reduces exposure to ineffective medications and associated side effects.

Furthermore, personalized dosing strategies ensure that patients receive the most appropriate therapeutic regimen, enhancing treatment safety and improving overall patient outcomes. As this approach becomes more widely adopted, it is expected to significantly advance the management of sJIA and reinforce the market's growth trajectory.

Key Market Players

  • Novartis AG
  • Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Bristol - Myers Squibb Company
  • Cadila Healthcare Ltd.
  • Genetech, Inc.
  • LATAM Pharma
  • Alteogen Inc.
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc

Report Scope:

In this report, the Global Systemic Juvenile Idiopathic Arthritis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Systemic Juvenile Idiopathic Arthritis Market, By Treatment Type:

  • Drug Treatment
  • Biologics
  • Other

Global Systemic Juvenile Idiopathic Arthritis Market, By Route of Administration:

  • Oral
  • Injectables
  • Other

Global Systemic Juvenile Idiopathic Arthritis Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Systemic Juvenile Idiopathic Arthritis Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Systemic Juvenile Idiopathic Arthritis Market.

Available Customizations:

Global Systemic Juvenile Idiopathic Arthritis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Systemic Juvenile Idiopathic Arthritis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Drug Treatment {Anti-inflammatories (NSAIDS), Tumor Necrosis Factor (TNF) Blockers, Muscle Relaxants, Immune Suppressants Drugs, Disease Modifying Antirheumatic Drugs, Others}, Biologics, Other)
    • 5.2.2. By Route of Administration (Oral, Injectables, Other)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Systemic Juvenile Idiopathic Arthritis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Mexico Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Canada Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Systemic Juvenile Idiopathic Arthritis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Germany Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Systemic Juvenile Idiopathic Arthritis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. South Korea Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. Japan Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. South America Systemic Juvenile Idiopathic Arthritis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Systemic Juvenile Idiopathic Arthritis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Systemic Juvenile Idiopathic Arthritis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (In case of listed companies)
    • 15.1.5. Recent Developments
    • 15.1.6. SWOT Analysis
  • 15.2. Hoffmann-La Roche Ltd
  • 15.3. Takeda Pharmaceutical Company Limited
  • 15.4. Bristol - Myers Squibb Company
  • 15.5. Cadila Healthcare Ltd.
  • 15.6. Genetech, Inc.
  • 15.7. LATAM Pharma
  • 15.8. Alteogen Inc.
  • 15.9. Johnson & Johnson
  • 15.10. Momenta Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer